DGAP-News

Airbion GmbH: ​​​​​​​Airbion: German company challenges COVID-19 viruses and other ultrafine particles - Seite 3

Broad target group and high sales revenue objectives beyond COVID-19 / Fine dust as a global problem

Airbion has set itself ambitious goals for the coming years. In the medium-term the provider of innovative air purification technology is striving with the Airbion devices for annual sales revenues of more than EUR 100 million. This expectation is underpinned by the high demand due to the current COVID-19 pandemic and a constantly increasing need for clean air against the backdrop of increasing (ultra) fine dust contamination in the worldwide metropolises. According to expert assessments, around 4.5 million people die every year of the sequelae of fine dust. Cancer, cardiovascular diseases and allergies are triggered by ultrafine particles, and the global economic damage is huge, too: It is estimated to amount to USD 2.9 trillion per year. The market for air purification has, therefore, a correspondingly growing importance. In Europe alone, analytical studies have determined that USD 13.4 billion are annually spent on air purification. The annual growth is estimated to amount to an average of more than 8 percent during the coming seven years. In this connection it needs to be taken into account that these estimates by market experts still date back to the time before the COVID-19 pandemic. The Airbion devices are suited for use in offices, medical practices, stores and shops, schools, fitness studios and last, but not least in private households - because clean air for healthy breathing is an issue in almost all life situations.

Sale of Airbion devices through different channels

For the sale of the novel Airbion devices, the company relies on several channels. Apart from direct marketing to final customers through its own website www.airbion.com and social media channels, an external sales structure for B2B customers has been integrated. The focus is on healthcare, but other commercial customers are addressed as well.

Founder with major goals - Airbion as a game changer in air purification

Professor Dr. Gregor Luthe, the inventor of the VAPUR technology and Chief Scientific Officer (CSO) of Airbion: "We have a unique technology which has an extremely high effectiveness. As a rule, conventional filter solutions cannot achieve this. In this connection we can do completely without chemistry and waste disposal issues for contaminated filters. In the current COVID-19 pandemic our solution is a strong contribution to the creation of clean virus-free air at places where people meet, work and enjoy their leisure time. Here, we create clean air for breathing. With Airbion we make a contribution to allow for a more rapid and sustainable return to a normalized life. We intend to launch a device for large spaces based on the VAPUR technology and, moreover, we work on mobile solutions to be carried along in busses, trains and planes. But our solution remains of course highly necessary beyond the pandemic, because the purification of contaminated air by removing ultrafine particles plays a growing role in our industrialized world. The large number of advance orders did, therefore, not surprise me. I am glad that after many years of research and development work, we can now deliver and start a broad marketing of the Airbion devices. Airbion is a game changer for air purification - for the benefit or our device users, the environment and our investors."